Farmak JSC increased its medicine sales by 18.35%
Farmak JSC increased sales of medicines by 18.35%
According to the results of Q1 2018, Farmak JSC increased its sales by 18.35% to 1.1 billion UAH against Q1 2017. Proxima Research data.
“For eight years straight now Farmak has been the leader on the pharmaceutical market of the country*. The company has achieved such results due to quality and innovation. Over the past seven years Farmak has spent 2.8 billion hryvnyas on the development and modernization of production. Today, all the equipment of the Company is high-tech and ultra-modern. Production lines meet GMP, ISO requirements. Farmak’s focus is the manufacture of innovative biotech products. These include Flenox, insulin and its analogues, X-ray contrast agents. At the same time, we continue to produce basic drugs that have been on the market for a few decades,” said Volodymyr Kostiuk, acting Executive Director of Farmak JSC.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...